Zobrazeno 1 - 10
of 183
pro vyhledávání: '"Keith L. Davis"'
Publikováno v:
Drugs - Real World Outcomes, Vol 11, Iss 3, Pp 501-511 (2024)
Abstract Background In patients with heart failure with reduced ejection fraction (HFrEF), lower discharge heart rate (HR) is known to be associated with better outcomes. However, the effect of HR control on patient outcomes, and the demographic and
Externí odkaz:
https://doaj.org/article/50e3663bc67840b0b7746cf62ba834a9
Publikováno v:
Cancer Reports, Vol 6, Iss 1, Pp n/a-n/a (2023)
Abstract Background Lenvatinib monotherapy was approved in the United States for first‐line treatment of patients with unresectable hepatocellular carcinoma (uHCC) in 2018. This study assessed real‐world treatment patterns and outcomes of lenvati
Externí odkaz:
https://doaj.org/article/7978fcbd58964b1283c1d25a77f3219a
Autor:
Gilles Salles, Stephen J. Schuster, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali Smith, Ana Jiménez Ubieto, Keith L. Davis, Saurabh Nagar, Jie Zhang, Vamsi Bollu, Etienne Jousseaume, Roberto Ramos, Yucai Wang, Brian K. Link
Publikováno v:
HemaSphere, Vol 6, Iss 7, p e745 (2022)
This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with gr
Externí odkaz:
https://doaj.org/article/e780703b57a547aa9be64bc3cbede090
Autor:
Peter Hillmen, Jing Xie, Alan S. M. Yong, Catherine Waweru, Thuy Anh Sorof, Ravi K. Goyal, Keith L. Davis
Publikováno v:
eJHaem, Vol 2, Iss 2, Pp 219-227 (2021)
Abstract Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute for Health and Care Excellence in January 2017,
Externí odkaz:
https://doaj.org/article/64a0d007117945a597b923277fa9e33d
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2690-2702 (2021)
Abstract Background Information on overall survival (OS) and adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL) is mostly available from clinical trials. We therefore conducted a population‐based retrospective cohort study to
Externí odkaz:
https://doaj.org/article/ee10a73acaf446daa5e76ae59e569ae3
Publikováno v:
Cancer Medicine, Vol 8, Iss 8, Pp 3803-3810 (2019)
Abstract Introduction Contemporary data describing treatment patterns, adverse events (AEs), and outcomes in patients with chronic lymphocytic leukemia (CLL) in clinical practice are lacking. We conducted a retrospective cohort study and assessed tre
Externí odkaz:
https://doaj.org/article/8f0d4103cfdf4d6096dda24a3ec502d5
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 11, Pp 2494-2502 (2017)
Vaccination at age-appropriate intervals increases protection against morbidity and mortality; however, compliance rates among children remain low partly due to a complicated vaccination schedule. Use of combination vaccines reduces the number of inj
Externí odkaz:
https://doaj.org/article/a41e2cacb9854fd5a280547f8e3502b6
Autor:
Huamao Mark Lin, Keith L. Davis, James A. Kaye, Katarina Luptakova, Saurabh P. Nagar, Mohamad Mohty
Publikováno v:
Advances in Hematology, Vol 2019 (2019)
Background. Limited data are available from real-world practices in Europe describing prevailing treatment patterns and outcomes in relapsed/refractory multiple myeloma (RRMM), particularly by cytogenetic risk. Methods. A retrospective medical record
Externí odkaz:
https://doaj.org/article/d1602ce2e4904f4dab213fe183f4e6f9
Autor:
Keith L. Davis, Isabelle Côté, James A. Kaye, Estella Mendelson, Haitao Gao, Julian Perez Ronco
Publikováno v:
Advances in Hematology, Vol 2015 (2015)
Few trial-based assessments of ruxolitinib in patients with lower-risk myelofibrosis (MF) have been conducted, and no studies have made such assessments in a real-world population. We assessed changes in spleen size and constitutional symptoms during
Externí odkaz:
https://doaj.org/article/10c9d08710124b4fb09731fe3171098a
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 2, Iss 2 (2015)
**Background:** Docetaxel has been a standard of care for castration-resistant prostate cancer (CRPC) in the United States since 2004, yet little has been reported on its patterns of use in routine practice. To help understand these patterns, a retro
Externí odkaz:
https://doaj.org/article/af78ae7e785c4c59b409594d48c92c72